This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Translational Prostate Cancer
        • Women in Science
          Andrea Miyahira, Ph.D
        • Health Policy
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
    • Trials in Progress
      • DORA - PCCTC
      • IRONMAN - PCCTC
      • PROMISE - PCCTC
      • SPLASH Trial
      • Oral EPI-7386
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SUO 2022
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Conference Highlights

ESMO 2018

  • Press Releases
  • Kidney Cancer
  • Prostate Cancer
  • Bladder Cancer

ESMO 2018

ESMO 2018 Press Releases

  • 2018 ESMO Immuno-Oncology Award Goes to Cornelis Melief
  • Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden
  • Avelumab Plus Axitinib Significantly Improve Progression-Free Survival in Untreated Renal Cell Carcinoma
  • ESMO 2018: Nivolumab in Combination with Iipilimumab Shows Promising Results in Patients with Advanced Form of Bladder Cancer
  • Huge Variations Between Countries in Time for Reimbursement Decisions on New Cancer Drugs
View all (14 articles)

ESMO 2018 Kidney Cancer

  • ESMO 2018: Can Biology Help Guide Treatment Decisions in Renal Cancer?
  • ESMO 2018: Challenging Established Frontline Therapies in Renal Cancer
  • ESMO 2018: PRINCIPAL Study - Real-World Effectiveness of Pazopanib in Patients with Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
  • ESMO 2018: Activity of Cabozantinib After PD-1/PD-L1 Immune Checkpoint Blockade In Metastatic Clear Cell Renal Cell Carcinoma
  • ESMO 2018: Safety and Tolerability of Atezolizumab plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma: IMmotion 150 and IMmotion 151
View all (23 articles)

ESMO 2018 Prostate Cancer

  • ESMO 2018: Preliminary results from TRITON2: A Phase II Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Repair Gene Alterations
  • ESMO 2018: The Best of Munich 2018 Congress Genitourinary Tumors, Prostate
  • ESMO 2018: Improving Treatment Outcome by Manipulating the Immune System
  • ESMO 2018: Cabazitaxel Treatment in mCRPC Clinical Trials Compared to Usual Care In CAPRI: An Observational Study In The Netherlands
  • ESMO 2018: Improving Outcome by Optimizing Combination and Sequencing of Treatments
View all (37 articles)

ESMO 2018 Bladder Cancer

  • ESMO 2018: ABACUS, A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer
  • ESMO 2018: Comprehensive Biomarker Analyses and Updated Results of PURE-01 Study: Neoadjuvant Pembrolizumab in Muscle-Invasive Urothelial Bladder Carcinoma
  • ESMO 2018: Is There Still a Role for Chemotherapy in Bladder Cancer?
  • ESMO 2018: Overall Survival Results – RANGE, Ramucirumab and Docetaxel In Platinum-Refractory Urothelial Carcinoma
  • ESMO 2018: Neoadjuvant Therapy with Pembrolizumab Alone or in Combination with Cisplatin plus Gemcitabine for Locally Advanced Urothelial Cancer, A Phase Ib/2 Study
View all (12 articles)
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free